Roadmap on nanomedicine

TY - JOUR

T1 - Roadmap on nanomedicine

AU - Decuzzi, Paolo

AU - Peer, Dan

AU - Di Mascolo, Daniele

AU - Palange, Anna Lisa

AU - Manghnani, Purnima Naresh

AU - Moein Moghimi, S.

AU - Shadi Farhangrazi, Z.

AU - Howard, Kenneth A.

AU - Rosenblum, Daniel

AU - Liang, Tingxizi

AU - Chen, Zhaowei

AU - Wang, Zejun

AU - Zhu, Jun Jie

AU - Gu, Zhen

AU - Korin, Netanel

AU - Letourneur, Didier

AU - Chauvierre, Cédric

AU - van der Meel, Roy

AU - Kiessling, Fabian

AU - Lammers, Twan

N1 - Funding Information: The authors gratefully acknowledge support by the Dutch Research Council (NWO; ZonMW Vici Grant No. 016.176.622 to W.J.M. Mulder), the European Commission (EFRE: I3-STM #0800387, ERA-NET: NSC4DIPG), the European Research Council (ERC: #309495, #813086 and #864121), the German Research Foundation (DFG: GRK2375 (#331065168), SFB1066, SFB/TRR57) and the Aachen Interdisciplinary Center for Clinical Research (IZKF: #O3-2). Funding Information: Original content from this work may be used under the terms of the . Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI. EFRE I3-STM #0800387 ERA-NET NSC4DIPG FP7 Nanosciences, Nanotechnologies, Materials and new Production Technologies http://dx.doi.org/10.13039/100011263 2012 LARGE-6-309820 Nederlandse Organisatie voor Wetenschappelijk Onderzoek http://dx.doi.org/10.13039/501100003246 ZonMW Vici grant #016.176.622 Interdisziplin�res Zentrum f�r Klinische Forschung, Universit�tsklinikum W�rzburg http://dx.doi.org/10.13039/501100009379 O3-2 H2020 European Research Council http://dx.doi.org/10.13039/100010663 813086 Deutsche Forschungsgemeinschaft http://dx.doi.org/10.13039/501100001659 GRK2375 (#331065168) SFB1066 SFB/TRR57 JDRF http://dx.doi.org/10.13039/100008871 3-SRA-2015-117-Q-R and 1-PNF-2019-674-S-B National Science Foundation http://dx.doi.org/10.13039/100000001 1708620 Novo Nordisk Fonden http://dx.doi.org/10.13039/501100009708 NNF17OC0028070 National Institutes of Health http://dx.doi.org/10.13039/100000002 R01 DK112939 01A1 Israel Ministry of Science and Technology 3-14350 Israel Science Foundation http://dx.doi.org/10.13039/501100003977 902/18 American Diabetes Association http://dx.doi.org/10.13039/100000041 1-15-ACE-21 Clinical and Translational Science Awards UL1 TR002489 Associazione Italiana per la Ricerca sul Cancro http://dx.doi.org/10.13039/501100005010 IG no 17664 FP7 Ideas: European Research Council http://dx.doi.org/10.13039/100011199 309495 ERC CoG no 616695 International Science and Technology Cooperation of Guangdong Province 2015A050502002 International Science and Technology Cooperation of Guangzhou City 2016201604030050 Compagnia di San Paolo http://dx.doi.org/10.13039/100007388 Ligurian Alliance for Nanomedicine against cancer yes � 2020 The Author(s). Published by IOP Publishing Ltd Creative Commons Attribution 4.0 license Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - Since the launch of the Alliance for Nanotechnology in Cancer by the National Cancer Institute in late 2004, several similar initiatives have been promoted all over the globe with the intention of advancing the diagnosis, treatment and prevention of cancer in the wake of nanoscience and nanotechnology. All this has encouraged scientists with diverse backgrounds to team up with one another, learn from each other, and generate new knowledge at the interface between engineering, physics, chemistry and biomedical sciences. Importantly, this new knowledge has been wisely channeled towards the development of novel diagnostic, imaging and therapeutic nanosystems, many of which are currently at different stages of clinical development. This roadmap collects eight brief articles elaborating on the interaction of nanomedicines with human biology; the biomedical and clinical applications of nanomedicines; and the importance of patient stratification in the development of future nanomedicines. The first article reports on the role of geometry and mechanical properties in nanomedicine rational design; the second articulates on the interaction of nanomedicines with cells of the immune system; and the third deals with exploiting endogenous molecules, such as albumin, to carry therapeutic agents. The second group of articles highlights the successful application of nanomedicines in the treatment of cancer with the optimal delivery of nucleic acids, diabetes with the sustained and controlled release of insulin, stroke by using thrombolytic particles, and atherosclerosis with the development of targeted nanoparticles. Finally, the last contribution comments on how nanomedicine and theranostics could play a pivotal role in the development of personalized medicines. As this roadmap cannot cover the massive extent of development of nanomedicine over the past 15 years, only a few major achievements are highlighted as the field progressively matures from the initial hype to the consolidation phase.

AB - Since the launch of the Alliance for Nanotechnology in Cancer by the National Cancer Institute in late 2004, several similar initiatives have been promoted all over the globe with the intention of advancing the diagnosis, treatment and prevention of cancer in the wake of nanoscience and nanotechnology. All this has encouraged scientists with diverse backgrounds to team up with one another, learn from each other, and generate new knowledge at the interface between engineering, physics, chemistry and biomedical sciences. Importantly, this new knowledge has been wisely channeled towards the development of novel diagnostic, imaging and therapeutic nanosystems, many of which are currently at different stages of clinical development. This roadmap collects eight brief articles elaborating on the interaction of nanomedicines with human biology; the biomedical and clinical applications of nanomedicines; and the importance of patient stratification in the development of future nanomedicines. The first article reports on the role of geometry and mechanical properties in nanomedicine rational design; the second articulates on the interaction of nanomedicines with cells of the immune system; and the third deals with exploiting endogenous molecules, such as albumin, to carry therapeutic agents. The second group of articles highlights the successful application of nanomedicines in the treatment of cancer with the optimal delivery of nucleic acids, diabetes with the sustained and controlled release of insulin, stroke by using thrombolytic particles, and atherosclerosis with the development of targeted nanoparticles. Finally, the last contribution comments on how nanomedicine and theranostics could play a pivotal role in the development of personalized medicines. As this roadmap cannot cover the massive extent of development of nanomedicine over the past 15 years, only a few major achievements are highlighted as the field progressively matures from the initial hype to the consolidation phase.

KW - Atherosclerosis

KW - Cancer therapy

KW - Diabetes

KW - Nanomedicine

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=85093117132&partnerID=8YFLogxK

U2 - 10.1088/1361-6528/abaadb

DO - 10.1088/1361-6528/abaadb

M3 - Journal article

C2 - 33043901

AN - SCOPUS:85093117132

SN - 0957-4484

VL - 32

JO - Nanotechnology

JF - Nanotechnology

IS - 1

M1 - 012001

ER -